@Dubya_B It looks like this was addressed to me, although it wouldn’t be obvious, if it weren’t for the capitalized “you”, by which I somehow inferred you meant me. Still, this is most helpful, thank you!
Maybe you can answer the question @Borax did not want to/couldn’t answer. Let me copy the question again here:
Let me also copy an excerpt from the paper you just posted. I would like to have my question answered, if at all possible, in light of this key passage from the paper, which I think sums up the theory well:
<<We postulate that a significant 32%-94% reduction of serum and cellular concentrations of DHT, depending on the 5ARI medication, and the resulting DHT surge following 5ARI withdrawal, can trigger the above listed molecular mechanisms and resulting persisting effects.
We propose that reducing DHT (via 5AR inhibition) leads to AR overexpression and hypersensitivity of the AR while on the medication. This hypersensitive state of the AR is maintained for an unknown duration after 5ARI withdrawal. The combination of a hypersensitive AR, and the return of baseline DHT levels after 5ARI withdrawal, results in a sharply overexpressed AR signal. This in turn triggers an AR negative autoregulation mechanism, which silences the overexpressed AR signal.>>